NCT04898634 trial: what clinicians have said so far
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
- NCT04898634 ↗
- Active, not recruiting
- Janssen Research & Development, LLC
- Focused size, estimated: 1–150 verified statements once built
Discussed at: 2026 ASCO Genitourinary Cancers Symposium, SITC 2026
We haven't built an HCP commentary report on NCT04898634 (pasritamig in metastatic castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04898634 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Prostatic Neoplasms
- Interventions
- JNJ-78278343
- Arms
- JNJ-78278343 · Experimental
- Enrollment
- 216
- Primary outcomes
- Part 1 and 2: Number of Participants With Adverse Events (AEs)
- Part 1 and 2: Number of Participants With AEs by Severity
- Part 1: Number of Participants With Dose-Limiting Toxicity (DLT)
- Sponsor
- Janssen Research & Development, LLC
- Start
- Jul 13, 2021
- Primary completion
- Mar 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04898634 · updated Nov 3, 2026
Publications
linked from the registry- Stein MN, Vinceneux A, Robbrecht D, Doger B, Autio KA, Schweizer MT, Calvo E, Medina L, Van Dongen M, Deville JL, Bernard-Tessier A, Ghosh D, Shotts K, Shen F, Jaiprasart P, Chaudhary R, Wu S, Cartee L, Schnepp R, Gaut D, Lauring J, Wang SC, Villalobos VM, Baldini C. Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. J Clin Oncol. 2025 Aug;43(22):2515-2526. doi: 10.1200/JCO-25-00678. Epub 2025 Jun 1. PubMed 40450573